Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17977200 | 0.90 | PARP1 (0.42) | PARP1PTGES2AKT1PIK3CAMTOR | |
| SCHEMBL3117995 | 0.82 | PARP1 (0.49) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| SCHEMBL27593112 | 0.78 | PARP1 (0.45) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| SCHEMBL30402468 | 0.78 | STAT3 (0.41) | PARP1PTGES2CA2CA1CA9 | |
| Hydrochloric Acid SCHEMBL28751198 | 0.77 | PARP1 (0.44) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| SCHEMBL10664550 | 0.76 | ACLY (0.44) | PTGES2CA2CA1CA9CA6 | |
| SCHEMBL38653299 | 0.76 | PARP1 (0.43) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| Bromobenzene SCHEMBL28736670 | 0.73 | PARP1 (0.41) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| SCHEMBL15300130 | 0.72 | PARP1 (0.39) | PARP1AKT1PIK3CAMTORAKR1C3 | |
| SCHEMBL30016297 | 0.72 | PARP1 (0.37) | PARP1PTGES2CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0132230-B1 | PROCESS FOR THE PREPARATION OF SULFONYL UREA | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | claimed |
| EP-0132230-A2 | Process for the preparation of sulfonyl urea | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | claimed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729515-A1 | NEW ACYLSULFONAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4692094-A1 | SULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-114072394-A | Acylsulfonamides for the treatment of cancer | 拜耳股份公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2010002802-A1 | PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-0132230-B1 | PROCESS FOR THE PREPARATION OF SULFONYL UREA | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | disclosed |
| US-4656273-A | Process for producing sulfonylureas | CIBA-GEIGY CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0132230-A2 | Process for the preparation of sulfonyl urea | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | PARP1 828/4885PTGES2 3466/4885AKT1 2612/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | PARP1 828/4885PTGES2 3466/4885AKT1 2612/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | PARP1 2001/4885PTGES2 1718/4885AKT1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.